巴比妥臨床檢測卡

廣州健侖生物科技有限公司

【包裝規(guī)格】 

1人份/袋、40人份/盒

本品采用競爭抑制法和膠體金免疫層析技術(shù)，用于定性檢測人體尿液中的代謝物苯甲酰愛康寧，適用于藥物濫用的初步篩查。

主營品牌：美國NovaBios、美國Cortez、國產(chǎn)創(chuàng)侖等等。

主要用途：篩查違禁品濫用殘留、麻醉藥殘留、興奮藥物殘留等等。

檢測范圍：嗎啡、KET、mamp、MDMA、BZO、THC、巴比妥、MTD、BAR、MDMA、AMP、BUP、PCP、TCA、OXY、MET等等。

產(chǎn)品特點(diǎn)：可以根據(jù)需求自主訂制多聯(lián)卡。多聯(lián)卡自由組合，從二聯(lián)到十五聯(lián)都可以訂制。

廣州健侖生物長期供應(yīng)各種違禁品檢測試紙、違禁品檢測卡、違禁品檢測試劑盒、藥篩試紙、藥篩試劑盒、嗎啡檢測試劑盒、巴比妥檢測試劑盒等。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

如需訂購或者了解請以下或

mob： 楊   ： 

以下可以自由COMBO多聯(lián)檢測卡：

巴比妥臨床檢測卡

更多產(chǎn)品說明可通過下方的進(jìn)行了解w the test device, urine specimen, and/or controls to reach room temperature (15-30oC) prior to t(-) (+) 
Cortez BUP 
Test 
GC/MS 
Negative 
(Less than 
–25% cut off) 
Near cutoff 
negative 
(between –
25% and c/o 
Near cutoff 
positive 
(between c/o 
and +25% 
GC/MS 
  Positive 
(greater than 
+25% cut off) 
Percent 
agreement 
with GC/MS 
Positive 0 0 8 36 93.6 
Negative 59 13 3 0 100.00 
Total 59 13 11 36 

添加掃一掃二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【 市場部 】       楊永漢
【】 
【騰訊  】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號二期2幢101-103室

The harm of parasitic diseases remains a widespread public health problem. Of the six major tropical diseases that the joint initiative of the UNDP/World Bank/WHO recommended for the prevention of tropical diseases, except for leprosy, the remaining five categories are parasitic diseases, namely malaria and schistosomiasis ( Shistosomaiasis), filariasis, leishmaniasis, and trypanosomiasis. Anopheline-borne malaria is the most serious parasitic disease in tropical diseases. In addition, common diseases caused by parasites include paragonimiasis in crayfish, liver flukes in sashimi, cannibalosis in cantonensis, and ginger larvae in water chestnuts. [8] It is estimated that about 2.1 billion people live in malaria-endemic areas, with 100 million clinical cases each year and approximay 1 million to 2 million deaths. At present, there are more than 300 million people living in non-protected areas without any special anti-malaria measures, and most of Africa is a non-protected area. For this reason, at least 1 million children under the age of 14 die of malaria with malnutrition and other health problems each year in Africa alone. Schistosomiasis is endemic in 76 countries and regions, with approximay 200 million schistosomiasis patients and 500-600 million people infected. [9] The mosquito-borne lymphatic filariasis is affected by 250 million people. Among them, Bancroftian filariasis is global. There are about 900 million inhabitants living in the threatened areas in Southeast Asia, Africa, the Americas and the Pacific. Most tropical countries in the island countries are particularly serious. The tick-borne onychomycosis causes skin filariasis and river blindness. It is estimated that there are 17.6 million patients worldwide, which are widely distributed in Africa and Latin America, and that 15% of patients are blind in severe areas. The epidemic of leishmaniasis is mainly distributed in the tropical and subtropical regions. It has a worldwide distribution and there are approximay 400,000 newly infected patients each year. The disease is spreading in East Africa. Trypanosomiasis, of which about 45 million people are threatened by the infection of African trypanosomiasis (sleep disease); the number of Chagas disease (Chagas disease) infected in South America is at least 10 million. In addition, intestinal protozoal and helminthic infections (intestinal protozoal and helminthic infections) are also threatening human health. The important species are global amoebiasis, giardia lamblia, tsutsugamushi disease, whipworm disease, and hooking. Insect disease, tsutsugamushi disease, there are also some local intestinal helminthiasis, such as pig tapeworm, tapeworm and so on. Peters (1989) estimated that the number of locusts, whipworms, hookworms, and roundworms infected worldwide was 1.283 billion, 870 million, 716 million, and 360 million.